1.55 USD
+0.05 (+3.33%)
1.5 USD
-0.05 (-3.23%)
We assign a fundamental rating of 1 out of 10 to CPHI. CPHI was compared to 191 industry peers in the Pharmaceuticals industry. CPHI may be in some trouble as it scores bad on both profitability and health. CPHI does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year CPHI has reported negative net income.
CPHI had a positive operating cash flow in the past year.
In the past 5 years CPHI always reported negative net income.
In the past 5 years CPHI always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -26.56%, CPHI is in line with its industry, outperforming 53.93% of the companies in the same industry.
The Return On Equity of CPHI (-56.58%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.56% | ||
| ROE | -56.58% | ||
| ROIC | N/A |
ROA(3y)-24.28%
ROA(5y)-20.29%
ROE(3y)-65.01%
ROE(5y)-57.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CPHI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CPHI has been increased compared to 1 year ago.
CPHI has more shares outstanding than it did 5 years ago.
CPHI has a worse debt/assets ratio than last year.
2.2 Solvency
CPHI has an Altman-Z score of -4.78. This is a bad value and indicates that CPHI is not financially healthy and even has some risk of bankruptcy.
CPHI has a Altman-Z score of -4.78. This is in the lower half of the industry: CPHI underperforms 63.35% of its industry peers.
The Debt to FCF ratio of CPHI is 48.73, which is on the high side as it means it would take CPHI, 48.73 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 48.73, CPHI is in the better half of the industry, outperforming 73.82% of the companies in the same industry.
A Debt/Equity ratio of 0.53 indicates that CPHI is somewhat dependend on debt financing.
CPHI has a worse Debt to Equity ratio (0.53) than 63.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 48.73 | ||
| Altman-Z | -4.78 |
ROIC/WACCN/A
WACC7.34%
2.3 Liquidity
A Current Ratio of 0.51 indicates that CPHI may have some problems paying its short term obligations.
CPHI has a Current ratio of 0.51. This is amonst the worse of the industry: CPHI underperforms 92.15% of its industry peers.
CPHI has a Quick Ratio of 0.51. This is a bad value and indicates that CPHI is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.19, CPHI is doing worse than 93.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.51 | ||
| Quick Ratio | 0.19 |
3. Growth
3.1 Past
CPHI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.70%, which is quite impressive.
The Revenue for CPHI has decreased by -29.64% in the past year. This is quite bad
The Revenue for CPHI have been decreasing by -16.15% on average. This is quite bad
EPS 1Y (TTM)74.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.84%
Revenue 1Y (TTM)-29.64%
Revenue growth 3Y-22.27%
Revenue growth 5Y-16.15%
Sales Q2Q%10.91%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CPHI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
75.39% of the companies in the same industry are more expensive than CPHI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 110.68 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CPHI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.55
+0.05 (+3.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.52%
Inst Owner Change-52.77%
Ins Owners53.39%
Ins Owner Change0%
Market Cap7.78M
Revenue(TTM)4.40M
Net Income(TTM)-3.66M
Analysts0
Price TargetN/A
Short Float %0.17%
Short Ratio0.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.77 | ||
| P/FCF | 110.68 | ||
| P/OCF | 18.32 | ||
| P/B | 1.2 | ||
| P/tB | 355.3 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.58
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.01
FCFY0.9%
OCF(TTM)0.08
OCFY5.46%
SpS0.88
BVpS1.29
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.56% | ||
| ROE | -56.58% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 1.6% |
ROA(3y)-24.28%
ROA(5y)-20.29%
ROE(3y)-65.01%
ROE(5y)-57.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 48.73 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 19.75% | ||
| Cap/Sales | 8.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.51 | ||
| Quick Ratio | 0.19 | ||
| Altman-Z | -4.78 |
F-Score5
WACC7.34%
ROIC/WACCN/A
Cap/Depr(3y)8.82%
Cap/Depr(5y)14.6%
Cap/Sales(3y)3.86%
Cap/Sales(5y)4.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.84%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-29.64%
Revenue growth 3Y-22.27%
Revenue growth 5Y-16.15%
Sales Q2Q%10.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y106.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y148.16%
OCF growth 3YN/A
OCF growth 5YN/A
CHINA PHARMA HOLDINGS INC / CPHI FAQ
Can you provide the ChartMill fundamental rating for CHINA PHARMA HOLDINGS INC?
ChartMill assigns a fundamental rating of 1 / 10 to CPHI.
What is the valuation status for CPHI stock?
ChartMill assigns a valuation rating of 1 / 10 to CHINA PHARMA HOLDINGS INC (CPHI). This can be considered as Overvalued.
What is the profitability of CPHI stock?
CHINA PHARMA HOLDINGS INC (CPHI) has a profitability rating of 1 / 10.
How financially healthy is CHINA PHARMA HOLDINGS INC?
The financial health rating of CHINA PHARMA HOLDINGS INC (CPHI) is 1 / 10.